Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03585114 · ClinicalTrials.gov registry record · Phase 2

Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers

A Phase 2 study of Metastatic Prostate Cancer, sponsored by Columbia University.

Active
Registry status
Phase 2
Development phase
11
Enrollment target
1
Study location

NCT03585114 is a Phase 2 study of Metastatic Prostate Cancer that is active but no longer recruiting, run by Columbia University. The registered enrollment target is 11 participants, below the 186-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03585114, a Phase 2 study of Metastatic Prostate Cancer, is active but no longer recruiting, sponsored by Columbia University.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
11 participants
Enrollment target
1
Study location

Study Summary

Primary Objective: * To determine whether changes in uptake of \[18F\]DCFPyL PET/CT scans at baseline and after 6 weeks of treatment for metastatic castrate resistant prostate cancer, correlates with radiographic progression free survival (rPFS) as defined by Prostate Cancer Working Group 3 (PCWG3) criteria. Secondary Objectives: * To determine whether changes in uptake of \[18F\]DCFPyL PET/CT scans correlate with overall survival (OS) * To determine whether baseline SUVmax correlate with rPFS * To compare number of lesions detected with standard imaging at baseline and at the time of progression

Conditions Studied

Metastatic Prostate Cancer

Interventions

  • DRUG [F-18] DCFPyL
  • PROCEDURE PET/CT imaging

Study Locations (1)

New York

  • Columbia University Irving Medical Center - New York

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2018-12-11
Est. Completion 2022-12
Phase Phase 2

Sponsor

Columbia University

958 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03585114

The ClinicalTrials.gov registry entry for NCT03585114 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 186-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which [F-18] DCFPyL is the first listed.

NCT03585114 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03585114 about?

NCT03585114 is a clinical study titled "Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers". Primary Objective: * To determine whether changes in uptake of \[18F\]DCFPyL PET/CT scans at baseline and after 6 weeks of treatment for metastatic castrate resistant prostate cancer, correlates with radiographic progression free survival (rPFS) as defined by Prostate Cancer Working Group 3 (PCWG3)...

What is the current status of trial NCT03585114?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2018-12-11. Estimated completion is 2022-12.

What conditions does trial NCT03585114 study?

This clinical trial studies the following conditions: Metastatic Prostate Cancer.

What interventions are being tested in trial NCT03585114?

The interventions under investigation include: [F-18] DCFPyL (DRUG), PET/CT imaging (PROCEDURE).

Who is sponsoring clinical trial NCT03585114?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03585114 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Prostate Cancer

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.